Obviousness

As a technical patent analyst, I have analyzed the obviousness of U.S. Patent 12,171,916 ("the '916 patent") under 35 U.S.C. § 103, based on the provided prior art references. The following analysis outlines potential combinations of these references that would render the independent claims of the '916 patent obvious to a person having ordinary skill in the art (PHOSITA) as of the priority date of May 30, 2017.

Summary of Key Claim Elements

The independent claims (1, 7, 10, and 14) of the '916 patent are directed to a plasma collection system and method. The core features can be summarized as:

1. Using Donor Parameters: Determining a target collection volume for plasma based on the donor's weight and hematocrit.
2. Pre-Procedure Calculation: Calculating this target volume before the draw cycle begins (Claim 10).
3. Dynamic Recalculation: Re-evaluating the donor's hematocrit during the procedure and establishing a new target volume for subsequent draw cycles (Claim 1).
4. Electronic Data Input: Receiving donor parameters electronically from a separate control system (Claim 14).

Obviousness Analysis

A strong case for obviousness can be made by combining the teachings of foundational apheresis system patents with prior art that already recognizes the importance of monitoring hematocrit to control the collection process.

Ground 1: U.S. Patent 5,112,298 ('298) in view of a foundational system like U.S. Patent 4,086,924 ('924)

This combination would render claims 7, 10, and 1 obvious.

• What the references teach:

  • U.S. Patent 4,086,924 ('924) discloses the foundational architecture of an automated plasmapheresis system. It teaches a system with a blood separator (centrifuge), a first pump for drawing whole blood, a second pump for anticoagulant, and a controller that manages automated draw and return cycles. This reference establishes the basic hardware and operational framework claimed in the '916 patent.
  • U.S. Patent 5,112,298 ('298) is highly relevant as it explicitly teaches an apheresis system that monitors the hematocrit of the blood being processed. Crucially, the '298 patent teaches adjusting operational parameters, such as the anticoagulant flow rate, in response to the monitored hematocrit level. The stated goal is to optimize the procedure and ensure donor safety.

• Motivation to Combine:
  A person having ordinary skill in the art would have been motivated to implement the hematocrit monitoring and control strategy of the '298 patent on the foundational apheresis system of the '924 patent. The '298 patent establishes that hematocrit is a critical, dynamic variable that should be monitored to optimize the collection process. The '924 patent provides the platform for such a process.

  The motivation for this combination is driven by the clear and recognized need for improved precision and yield in plasma collection. By the priority date, it was well-known that regulatory collection limits (e.g., from the FDA) were based on donor weight and aimed at a specific volume of pure plasma, not the total volume of the plasma/anticoagulant mixture. The '298 patent's method of monitoring hematocrit provides the key piece of information needed to differentiate pure plasma from the total collected fluid. A PHOSITA would have found it obvious to use the monitored hematocrit value, along with the donor's weight, to calculate a precise target collection volume for pure plasma. This is not an inventive leap but rather the logical application of a known control parameter (hematocrit) to achieve a known goal (collecting a specific, regulated volume of plasma).

• Rendering the Claims Obvious:

  • Claims 7 and 10 (Determining a Target Volume): Combining '924 and '298 teaches a system that can monitor hematocrit. A PHOSITA would obviously use this data, along with the donor's weight, to calculate a target volume to meet regulatory requirements and optimize yield. Performing this calculation prior to the procedure (as in Claim 10) is a standard, prudent step in any medical procedure to establish goals and safety limits. The Japanese reference JPH0252665A, which teaches pre-calculating a collection amount, further supports the obviousness of this step.
  • Claim 1 (Dynamic Recalculation): Claim 1's key feature is recalculating the target volume mid-procedure. The '298 patent teaches monitoring hematocrit during the procedure and making adjustments because it recognizes that hematocrit can change. If the ultimate goal is to collect a precise target of pure plasma, and the key variable (hematocrit) for calculating that volume is changing, it would have been obvious to a PHOSITA to re-run the initial calculation with the updated hematocrit value. This is an obvious way to improve the accuracy of the process taught by '298. Instead of merely adjusting flow rates, one would adjust the final collection goal itself to ensure the target for pure plasma is not exceeded. This is an expected and predictable optimization, not a separate invention.

Ground 2: Addressing Claim 14 (Electronic Data Reception)

The limitation in Claim 14, which recites receiving donor parameters "electronically from a control system," would have been obvious to a PHOSITA by the 2017 priority date.

• Reasoning:
  The integration of medical devices with hospital or clinic information systems (like Electronic Health Records, or EHRs) was widespread practice long before 2017. The motivation is self-evident: to increase efficiency, reduce manual data entry errors, and improve patient safety. It would have been an obvious and routine design choice to equip the apheresis system from the '924/'298 combination with a standard electronic interface (e.g., Ethernet, Wi-Fi) to receive donor weight and hematocrit data from a central donor management system rather than relying on manual input from an operator. This constitutes the application of known computer networking principles to a known medical device and lacks an inventive step.

Conclusion

The claims of U.S. Patent 12,171,916 are likely invalid as obvious under 35 U.S.C. § 103. The foundational hardware and operational cycles were well-established by prior art such as U.S. Patent 4,086,924. The critical concept of monitoring a donor's hematocrit and adjusting system parameters in response was explicitly taught by U.S. Patent 5,112,298. A person of ordinary skill in the art would have been motivated to combine these teachings to calculate a more precise target plasma volume based on weight and hematocrit to improve yield and regulatory compliance. Extending this to pre-calculate the target, dynamically update it based on real-time data, and receive the initial data electronically are all obvious, predictable improvements based on standard engineering and medical practice at the time.